Reference
1. Alesha A Thai 1 , B.J.S., Lecia V Sequist 2 , Justin F Gainor 2 , Rebecca S Heist 3, Lung cancer. Lancet, 2021,.398 (10299): p. 535-554.
2. Tatiana V Denisenko 1 , I.N.B., Boris Zhivotovsky 2 3, Cell death-based treatment of lung adenocarcinoma. 2018 Jan 25;9(2) : p.:117.
3. Psallidas, I., et al., Malignant pleural effusion: from bench to bedside. European Respiratory Review An Official Journal of the European Respiratory Society, 2016. 25 (140): p. 189.
4. Hegde, P.S., J.J. Wallin, and C. Mancao. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics . in Seminars in Cancer Biology . 2017.
5. Wu, J., et al., Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother, 2020. 125 : p. 109746.
6. Wu, H., et al., The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer. Clin Lab, 2020. 66 (3).
7. Bi, H., et al., Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. Lab Med, 2023. 54 (4): p. 372-379.
8. Bes-Scartezini, F. and R. Saad Junior, Prognostic assessment of tumor markers in lung carcinomas. Rev Assoc Med Bras (1992), 2022.68 (3): p. 313-317.
9. Expert Committee on Vascular Targeted Therapy, C.S.o.C.O.E.C.o.N.-S.C.L.C., Chinese Society of Clinical Oncology and E.G.o.A.-A.D.T.f.N.-S.C.L.C.o.t.C.S.o.C. Oncology, Anti-angiogenic drug therapy for advanced non-small cell lung cancer Chinese Expert Consensus (2022 Edition). Natl Med J China,, 2022. December 27,Vol. 102, : p. No. 48.
10. Shuquan, M.C.L.H.a.H.G.M.Z.H.X.H.L.W., Analysis of triple multiple primary malignant neoplasms. Guangzhou Medicine, 2023.January, Vol. 54, : p. No. 1.
11. Expert Committee on Vascular Targeted Therapy of the Chinese Society of Clinical Oncology, E.C.o.N.-S.C.L.C.o.t.C.S.o.C.O., Expert Group on Anti-Angiogenic Drug Therapy for Non-Small Cell Lung Cancer of the Chinese Society of Clinical Oncology., Chinese Expert Consensus on Anti-Angiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer (2020 Edition). 2020: p. 2020,42(12):1063-1077. .
12. Åsa Kristina Öjlert 1 , A.R.H., Daniel Nebdal The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery. Molecular Oncology, 2019. 13 (5).
13. Chen, K., et al., Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions. Thoracic Cancer, 2020: p. 2021 Jan;12(2):218-226.
14. Su, D., et al., Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021. 11 : p. 634059.
15. Mazzaschi, G., et al., Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study. Clin Lung Cancer, 2022.